FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379331338> ?p ?o ?g. }

• W4379331338 endingPage "e16137" @default.
• W4379331338 startingPage "e16137" @default.
• W4379331338 abstract "e16137 Background: Conversion therapy achieve tumor downstaging and provide middle-advanced stage HCC patients with opportunities for radical resection. Lenvatinib combined with immune checkpoint inhibitors (ICIs) and FOLFOX-HAIC has shown high conversion success rates. This study aimed to evaluate the efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC as first-line conversion therapy in this population. Methods: Between April, 2021, and April, 2022, we retrospectively analyzed clinical data of HCC patients with BCLC stage B or C who underwent tislelizumab combined with lenvatinib and FOLFOX4-HAIC. The primary outcome included objective response rate (ORR), disease control rate (DCR), conversion resection rate (CRR) and treatment-related adverse events (TRAEs). Data were expressed as median(range). Results: A total of 18 patients (17 male, 1 female) completed conversion therapy assessment until the last follow-up time (December 27, 2022). The patients were characterized with a median age of 55.5 years (37-72), body mass index 24.9(19.8-33.9), 1 patient with BCLC stage B, 16 patients with BCLC stage C, and 1 patient with HCC postoperative recurrence with intrahepatic metastasis. According to mRECIST criteria, tumor shrinkage was observed in all patients, with an ORR of 94.4% (17/18, including 61.1% [11/18] complete response), DCR of 94.4% (17/18), and median time to response(mTTR) of 1.4 months (0.7-3.0). Successful conversion was observed in 11 (61.1%) of 18 patients per mRECIST. As of cut-off date, the actual CRR and pathological complete response(pCR) were 38.9% (7/18) and 57.1% (4/7), respectively. No surgical deaths occurred, and at the last follow-up review, there was disease free survival in all patients after operation. With a follow-up time of 20.7 months, median progression-free survival (PFS) and overall survival (OS) were not reached, with a 3- and 6-month progression-free survival rate of 94.4% and 83.3%. During the follow-up period, 6 patients developed disease progression with a median time to progression (mTTP) of 5.4 months (1-6.7), of whom 3 died due to disease progression. Most common TRAE was aspartate aminotransferase (AST) increased (16 patients, 88.9%). Grades ≥3 TRAEs occurred in 12 patients (66.7%), with only one grade 4 TRAE (AST increased). All TRAEs were tolerable and manageable. Conclusions: Tislelizumab combined with lenvatinib and FOLFOX4-HAIC showed high conversion rate and acceptable toxicity in the treatment of middle-advanced stage HCC, suggesting that this combination could be considered as a new conversion strategy in this population." @default.
• W4379331338 created "2023-06-05" @default.
• W4379331338 creator A5000753033 @default.
• W4379331338 creator A5012590006 @default.
• W4379331338 creator A5012851930 @default.
• W4379331338 creator A5024666296 @default.
• W4379331338 creator A5033511625 @default.
• W4379331338 creator A5043698718 @default.
• W4379331338 creator A5061867449 @default.
• W4379331338 creator A5068485790 @default.
• W4379331338 creator A5081888630 @default.
• W4379331338 creator A5085984577 @default.
• W4379331338 creator A5090371252 @default.
• W4379331338 date "2023-06-01" @default.
• W4379331338 modified "2023-09-23" @default.
• W4379331338 title "Efficacy and safety of tislelizumab combined with lenvatinib and FOLFOX4-HAIC in conversion therapy of middle-advanced stage hepatocellular carcinoma (HCC): A real-world retrospective study." @default.
• W4379331338 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e16137" @default.
• W4379331338 hasPublicationYear "2023" @default.
• W4379331338 type Work @default.
• W4379331338 citedByCount "0" @default.
• W4379331338 crossrefType "journal-article" @default.
• W4379331338 hasAuthorship W4379331338A5000753033 @default.
• W4379331338 hasAuthorship W4379331338A5012590006 @default.
• W4379331338 hasAuthorship W4379331338A5012851930 @default.
• W4379331338 hasAuthorship W4379331338A5024666296 @default.
• W4379331338 hasAuthorship W4379331338A5033511625 @default.
• W4379331338 hasAuthorship W4379331338A5043698718 @default.
• W4379331338 hasAuthorship W4379331338A5061867449 @default.
• W4379331338 hasAuthorship W4379331338A5068485790 @default.
• W4379331338 hasAuthorship W4379331338A5081888630 @default.
• W4379331338 hasAuthorship W4379331338A5085984577 @default.
• W4379331338 hasAuthorship W4379331338A5090371252 @default.
• W4379331338 hasConcept C126322002 @default.
• W4379331338 hasConcept C141071460 @default.
• W4379331338 hasConcept C143998085 @default.
• W4379331338 hasConcept C146357865 @default.
• W4379331338 hasConcept C151730666 @default.
• W4379331338 hasConcept C197934379 @default.
• W4379331338 hasConcept C2776264508 @default.
• W4379331338 hasConcept C2778019345 @default.
• W4379331338 hasConcept C2778695046 @default.
• W4379331338 hasConcept C71924100 @default.
• W4379331338 hasConcept C86803240 @default.
• W4379331338 hasConcept C90924648 @default.
• W4379331338 hasConceptScore W4379331338C126322002 @default.
• W4379331338 hasConceptScore W4379331338C141071460 @default.
• W4379331338 hasConceptScore W4379331338C143998085 @default.
• W4379331338 hasConceptScore W4379331338C146357865 @default.
• W4379331338 hasConceptScore W4379331338C151730666 @default.
• W4379331338 hasConceptScore W4379331338C197934379 @default.
• W4379331338 hasConceptScore W4379331338C2776264508 @default.
• W4379331338 hasConceptScore W4379331338C2778019345 @default.
• W4379331338 hasConceptScore W4379331338C2778695046 @default.
• W4379331338 hasConceptScore W4379331338C71924100 @default.
• W4379331338 hasConceptScore W4379331338C86803240 @default.
• W4379331338 hasConceptScore W4379331338C90924648 @default.
• W4379331338 hasIssue "16_suppl" @default.
• W4379331338 hasLocation W43793313381 @default.
• W4379331338 hasOpenAccess W4379331338 @default.
• W4379331338 hasPrimaryLocation W43793313381 @default.
• W4379331338 hasRelatedWork W2370316128 @default.
• W4379331338 hasRelatedWork W2791311396 @default.
• W4379331338 hasRelatedWork W3026091304 @default.
• W4379331338 hasRelatedWork W4214929818 @default.
• W4379331338 hasRelatedWork W4240236077 @default.
• W4379331338 hasRelatedWork W4251581028 @default.
• W4379331338 hasRelatedWork W4251656722 @default.
• W4379331338 hasRelatedWork W4360619981 @default.
• W4379331338 hasRelatedWork W4361955616 @default.
• W4379331338 hasRelatedWork W4361955619 @default.
• W4379331338 hasVolume "41" @default.
• W4379331338 isParatext "false" @default.
• W4379331338 isRetracted "false" @default.
• W4379331338 workType "article" @default.